Show simple item record

dc.contributor.authorGeorgieva, Zoya G
dc.contributor.authorDӧffinger, Rainer
dc.contributor.authorKumararatne, Dinakantha
dc.contributor.authorColes, Alasdair J
dc.contributor.authorMcCarthy, Claire
dc.date.accessioned2022-05-25T18:03:02Z
dc.date.available2022-05-25T18:03:02Z
dc.date.issued2022-06
dc.date.submitted2021-04-29
dc.identifier.issn1352-4585
dc.identifier.other10.1177_13524585211046786
dc.identifier.urihttps://www.repository.cam.ac.uk/handle/1810/337474
dc.description.abstractBACKGROUND: Despite impressive efficacy in immunocompetent individuals, the immunogenicity of a single dose of COVID-19 vaccine in B-cell-deplete patients remains unknown. OBJECTIVES: We aimed to quantify real-world vaccine immunogenicity in ocrelizumab recipients. METHODS: We measured post-vaccination SARS-COV-2 immunoglobulin G (IgG) in ocrelizumab recipients using a highly sensitive Luminex assay. RESULTS: 44.1% of patients had detectable SARS-COV-2-IgG 21+ days after one vaccine dose, regardless of vaccine type (AZD1222 vs BNT162b2, odds ratio (OR) = 0.62, 95% confidence interval (CI) = 0.157-2.32, p = 0.72). B-cell count strongly predicted seroconversion (β1 = 12.38, 95% CI = 4.59-20.16, p = 0.0029), but undetectable B-cells did not preclude it. The second vaccine seroconverted 53% of the patients who had not already responded to dose 1. CONCLUSION: Humoral response after one COVID-19 vaccine dose is lower than expected in CD20-deplete patients.
dc.languageen
dc.publisherSAGE Publications
dc.subjectShort Reports
dc.subjectOcrelizumab
dc.subjectSARS-COV-2
dc.subjectCOVID-19
dc.subjectvaccination
dc.subjectantibodies
dc.titleDiminished seroconversion following a single SARS-COV-2 vaccine in ocrelizumab-treated relapsing-remitting multiple sclerosis patients.
dc.typeArticle
dc.date.updated2022-05-25T18:03:01Z
prism.endingPage1130
prism.issueIdentifier7
prism.publicationNameMult Scler
prism.startingPage1126
prism.volume28
dc.identifier.doi10.17863/CAM.84888
dcterms.dateAccepted2021-08-22
rioxxterms.versionofrecord10.1177/13524585211046786
rioxxterms.versionVoR
rioxxterms.licenseref.urihttps://creativecommons.org/licenses/by/4.0/
rioxxterms.licenseref.startdate2021-10-01
dc.contributor.orcidGeorgieva, Zoya [0000-0002-9531-8884]
dc.contributor.orcidColes, Alasdair [0000-0003-4738-0760]
dc.identifier.eissn1477-0970
pubs.funder-project-idWellcome Trust (204017/Z/16/Z)
cam.issuedOnline2021-10
rioxxterms.freetoread.startdate2021-10-01
rioxxterms.freetoread.startdate2021-10-01


Files in this item

Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record